Prostate-Specific Membrane Antigen (PSMA) Uptake in a Pancreatic Neuroendocrine Tumor (pNET) Bearing Patient Abstract #1705

Introduction: Prostate-specific membrane antigen (PSMA) is a transmembrane protein overexpressed on both prostate epithelial malignant cells and endothelial cells of tumor-associated neovasculature of many solid cancers. PSMA has been investigated already as a target in staging and detection of prostate cancer
Aim(s): Case Report
Materials and methods: A 65-year old male with multiple endocrine neoplasia syndrome (MEN-1) and an history of radically resected prostatic adenocarcinoma. Baseline 68Ga-PET/CT scan documented elevated receptor expression in the head of pancreas and multiple hepatic lesions. FNAB of liver lesion was diagnostic for pancreatic neuroendocrine tumor pNET (Ki67 5%). At diagnosis the patient began SSA treatment which was associated 2 years later with Everolimus due to hepatic progression. For a mild raise in PSA the patient underwent 67Ga-PSMA PET/CT scan which demonstrated a PSMA avid uptake in known neuroendocrine lesions (SUV max 96)
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Elisabetta Grego

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1023 Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience
Introduction: STZ is the only FDA-approved antiblastic drug for well-/moderately-differentiated NETs. To date, no clear therapeutic sequence is defined for medical treatment of advanced pNETs.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Sara Cingarlini
#1722 New MEN-1 Gene Mutation Implicated in Familiar MEN-1 Syndrome Onset
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic syndrome associated with an increased risk of developing parathyroid, pituitary and pancreatic neuroendocrine tumors. MEN1 has an autosomal dominant pattern of hereditability and it is usually related to mutations in menin coding gene
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Elisabetta Grego
#1706 Effectiveness of Chemoterapy in Advanced PanNETs with ki67<55%: Monocentric Experience
Introduction: Pancreatic Neuroendocrine Tumors (panNETs) are neoplasms with heterogeneous clinical behaviour. There is no standard treatment.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Maria Antista
#999 Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study
Introduction: Criteria other than RECIST are not validated for evaluation of response during treatment in pancreatic neuroendocrine tumors (pNETs). Preliminary evidence favors antiangiogenic properties of E.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sara Cingarlini
Keywords: everolimus, pNET, P-CT
#1447 Clinicopathologic Features, Management and Outcome of Neuroendocrine Tumors (NETs) in MEN1: The Verona Multidisciplinary PlaNET Group
Introduction: Gastroenteropancreatic endocrine tumors (GEP-NETs) are a frequent manifestation of MEN1. They represent an important prognostic factor in these patients. There is still a debate on their management, mainly on surgical strategy, due to their multicentricity and high recurrence rate.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Elisa Cosaro
Keywords: MEN1, GEP-NET, management